Univercells Proceeds on Pathway for US Markets

Biomanufacturing technology company Univercells SA is building on its long-term strategy, notably the development of its US-based activities, with the appointment of Douglas Neugold as Chairman of its Board of Directors.

Mr Neugold has more than 30 years industry experience and led ATMI Inc to a global leadership position as a supplier of sophisticated materials and delivery systems used in the manufacture of computer chips and displays, with subsequent development into other high growth technology intensive industries, most notably single-use systems for bioprocessing.

As CEO of ATMI, Mr. Neugold partnered with Univercells’ founders Hugues Bultot and José Castillo to fund and help strategically develop their previous biotech start-up, Artelis. ATMI eventually acquired the company, before its own acquisition by Pall in May of 2014. Pall was subsequently acquired by Danaher in the same year.

“I have been following the growth and evolution of Univercells from the beginning, serving as a strategic advisor. I am proud and excited to take a more active role in helping drive its further development and achieve its objectives, which I see as making significant contributions to improving global health, most especially in emerging markets” said Mr. Neugold.

“We are very pleased to welcome Mr. Neugold to our board. He is very well known for his entrepreneurial mindset, his dynamic skills, his strategic insight and his ability to grow small to medium-size businesses into large corporations,” said Hugues Bultot, CEO of Univercells. “His tremendous experience and deep understanding of Univercells’ technology and mission make him ideally suited to lead our board of directors and create new opportunities that support our vision for Univercells’ future.”